

Noninvasive prenatal test for genetic abnormalities, 11/13

PAML, through a partnership with Verinata Health, is now offering the Verifi prenatal test for all patients within the network desiring noninvasive prenatal testing to detect Down syndrome, Edwards syndrome, Patau syndrome, and sex chromosome abnormalities, the most common genetic abnormalities tested for during pregnancy.

The Verifi prenatal blood test analyzes genetic material (or cell-free DNA) naturally found in a pregnant woman's blood to detect the most common fetal chromosome abnormalities. The test can be offered to women at high risk of having a child with a disorder caused by an abnormal number of chromosomes as early as 10 weeks of pregnancy and represents a major advance in prenatal testing, providing genetic information about the fetus without the risk associated with invasive amniocentesis or chorionic villus sampling tests. The Verifi prenatal test offers improved sensitivity and specificity over traditional screening tests, and for the majority of high-risk women, it provides reassurance that their fetus is not affected with the most common genetic aneuploidies.

All tests will be run in Verinata Health's CLIA-certified laboratory in California. Results are returned to the physician in three to six business days. While the Verifi test does not replace invasive procedures, it may dramatically reduce the number of unnecessary invasive procedures performed.

[**PAML**](#), 800-541-7891